ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development Post author: Post published:November 13, 2023 Post category:uncategorized ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. You Might Also Like Mount Sinai BioDesign expands collaboration with MedTech community to enhance medical innovation October 3, 2024 Study reveals high alcohol consumption in men increases mortality risks in China November 28, 2023 Fatty liver disease linked to higher mortality risk from many common diseases March 24, 2025
Mount Sinai BioDesign expands collaboration with MedTech community to enhance medical innovation October 3, 2024